NasdaqGS:TEMLife Sciences
Tempus AI’s Record ASCO Showing Tests Cancer Data And Revenue Story
Tempus AI had 37 abstracts accepted for presentation at the 2026 ASCO Annual Meeting, its largest scientific showing at this conference.
The work centers on the company’s multimodal data platform and AI driven insights in cancer care.
The volume of accepted research highlights growing interest from the oncology research community in Tempus AI’s technology.
Tempus AI (NasdaqGS:TEM) is drawing attention not just for its technology, but for how often that technology is now showing up in high...